Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEVI STRAUSS & COLEVI · Entity 3651 | Director | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEVI STRAUSS & CO
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 181,261 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Grant · Acquired 54 · Balance 181,261 F1: Represents dividend equivalent rights (DERs), each of which represents a contingent right to receive one share of the issuer's Class A Common Stock upon settlement. The DERs shall vest as to 100% of the shares on the earlier of the day before the next Annual Stockholder Meeting or the first anniversary of the date of grant of the underlying award. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 14,463 |
Reported balance
After 2026-08-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-05 · Grant · Acquired 92 · Balance 14,463 F2: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: Represents DERs, each of which represents a contingent right to receive one share of the issuer's Class B Common Stock upon settlement. The DERs are fully vested. The underlying shares of Class B Common Stock issuable pursuant to the DERs are subject to a deferral delivery feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividend equivalent rights (DERs), each of which represents a contingent right to receive one share of the issuer's Class A Common Stock upon settlement. The DERs shall vest as to 100% of the shares on the earlier of the day before the next Annual Stockholder Meeting or the first anniversary of the date of grant of the underlying award.
F2: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F3: Represents DERs, each of which represents a contingent right to receive one share of the issuer's Class B Common Stock upon settlement. The DERs are fully vested. The underlying shares of Class B Common Stock issuable pursuant to the DERs are subject to a deferral delivery feature.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 28,606 · Balance 15,000 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock award held by a non-employee member of the Issuer board then outstanding and not vested was canceled and converted into the right to receive the Per Share Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2021 Filed Nov 18, 2021 22:03 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 81 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065524 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,289 F1 · shares: With respect to 36 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. With respect to 66 of the DERs, the DERs shall vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. With respect to 15 of the DERs for Class A Common Stock, the DERs shall vest as to 100% of the shares on the first anniversary of the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A Common Stock or Class B Common Stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A Common Stock or Class B Common Stock, as appropriate. Read SEC document |
| August 18, 2021 Filed Sep 2, 2021 21:16 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 94 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054505 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,208 F1 · shares: With respect to 36 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. With respect to 79 of the DERs, the DERs shall vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. With respect to 15 of the DERs for Class A Common Stock, the DERs shall vest as to 100% of the shares on the first anniversary of the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A Common Stock or Class B Common Stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A Common Stock or Class B Common Stock, as appropriate. Read SEC document |
| July 15, 2021 Filed Jul 20, 2021 01:16 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 5,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-047314 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,114 F1 · shares: The shares are represented by restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. The RSUs will vest in full on July 15, 2022. Read SEC document |
| May 25, 2021 Filed May 27, 2021 00:20 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 72 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036097 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,659 F1 · shares: With respect to 35 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:04 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 7,551 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0001479290-21-000106 · wf-form4_162042863798920.xml · derivative · entry 2 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,551 Underlying: Common Stock · 7,551 shares Expires 2031-05-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Ms. Beraud's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 05, 2021 Filed May 7, 2021 19:04 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 4,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-21-000106 · wf-form4_162042863798920.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,013 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Ms. Beraud's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 02:29 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 56 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016621 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,587 F1 · shares: With respect to 27 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 23:06 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 12,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043081 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,531 F1 · shares: The shares are represented by restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. The RSUs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 12,000 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001479290-20-000071 · wf-form4_158958268428146.xml · derivative · entry 2 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-05-13 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Ms. Beraud's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document |
| May 14, 2020 Filed May 15, 2020 18:45 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-20-000071 · wf-form4_158958268428146.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on May 14, 2021, the one year anniversary from the grant date, subject to Ms. Beraud's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| May 08, 2020 Filed May 12, 2020 22:51 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-028640 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,009 F1 · shares: With respect to 106 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| May 08, 2020 Filed Jun 1, 2020 20:30 UTC Amendment | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 208 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033192 · doc4a.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,082 F1 · shares: With respect to 164 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:48 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-012669 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,874 F1 · shares: With respect to 106 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| October 17, 2019 Filed Jan 8, 2020 21:34 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002537 · doc5.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,739 F1 · shares: With respect to 230 dividend equivalent rights (DER), each of those DERs represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The DERs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F2 · price: Settlement of DER in connection with restricted stock units (RSU). The rights accrued when and as dividends were paid on the Issuer's Class A common stock or Class B common stock, as appropriate, and became exercisable proportionately with the RSU to which they are related. Each DER is the economic equivalent of one share of the Issuer's Class A common stock or Class B common stock, as appropriate. Read SEC document |
| June 20, 2019 Filed Aug 9, 2019 20:16 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | GrantClass A Common Stock | 7,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-045338 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,447 F1 · shares: The shares are represented by restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement. The RSUs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 19:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantStock Option (Right to buy) · Derivative | 18,000 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001479290-19-000069 · wf-form4_155986406056598.xml · derivative · entry 2 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-03 F2 · derivative.exercise_date: The shares subject to this stock option shall vest on June 4, 2020, the one year anniversary of the grant date, subject to Ms. Beraud's Continuous Service (as defined in the Plan) through such vesting date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 19:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-19-000069 · wf-form4_155986406056598.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Represents an annual restricted stock award (the "RSA"). The shares underlying the RSA shall vest on June 4, 2020, the one year anniversary from the grant date, subject to Ms. Beraud's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:15 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherClass B Common Stock · Derivative | 77,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021531 · doc4.xml · derivative · entry 3 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,410 Underlying: Class A Common Stock · 77,410 shares Expires not disclosed F1 · security: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F4 · security: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:15 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherClass A Common Stock | 43,330 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021531 · doc4.xml · nonDerivative · entry 2 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,330 F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F3 · shares: Each share is represented by an RSU, 2,400 of which are issuable in respect of dividend equivalent rights on the RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. The RSUs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Read SEC document |
| March 25, 2019 Filed Mar 28, 2019 00:15 UTC | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherCommon Stock | 120,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021531 · doc4.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F2 · shares: 43,330 of the shares are represented by restricted stock units (RSUs), 2,400 of which are issuable in respect of dividend equivalent rights on the RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in a series of three (3) equal installments on the dates that are thirteen (13), twenty-four (24) and thirty-six (36) months following the date of grant. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Read SEC document |
| March 25, 2019 Filed Apr 21, 2023 22:20 UTC Amendment | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherClass B Common Stock · Derivative | 43,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025241 · doc4a.xml · derivative · entry 4 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,740 Underlying: Class A Common Stock · 43,330 shares Expires not disclosed F2 · security: This Form 4/A is being filed to correct the disclosure relating to such RSUs (the "Class B RSUs") set forth in the Form 4 filed on March 27, 2019 (the "Original Form 4"), which were inadvertently disclosed in Table I instead of Table II in the Original Form 4. DERs issued with regard to the Class B RSUs after the date of the Original Form 4 were also incorrectly reported on Table I instead of Table II, as a result of the initial misclassification. F3 · security: Each share is represented by a restricted stock unit (RSU) that may be settled in shares of Class B Common Stock, including RSUs previously issued in the form of dividend equivalent rights (DERs). Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. The RSUs vest in a series of three equal installments on the dates that are 13, 24 and 36 months following the date of grant. Certain of such RSUs are subject to a deferral delivery feature. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| March 25, 2019 Filed Apr 21, 2023 22:20 UTC Amendment | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherClass B Common Stock · Derivative | 77,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025241 · doc4a.xml · derivative · entry 3 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,410 Underlying: Class A Common Stock · 77,410 shares Expires not disclosed F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| March 25, 2019 Filed Apr 21, 2023 22:20 UTC Amendment | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherCommon Stock | 43,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025241 · doc4a.xml · nonDerivative · entry 2 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · security: This Form 4/A is being filed to correct the disclosure relating to such RSUs (the "Class B RSUs") set forth in the Form 4 filed on March 27, 2019 (the "Original Form 4"), which were inadvertently disclosed in Table I instead of Table II in the Original Form 4. DERs issued with regard to the Class B RSUs after the date of the Original Form 4 were also incorrectly reported on Table I instead of Table II, as a result of the initial misclassification. F3 · shares: Each share is represented by a restricted stock unit (RSU) that may be settled in shares of Class B Common Stock, including RSUs previously issued in the form of dividend equivalent rights (DERs). Each RSU represents a contingent right to receive one share of the Issuer's Class B Common Stock upon settlement. The RSUs vest in a series of three equal installments on the dates that are 13, 24 and 36 months following the date of grant. Certain of such RSUs are subject to a deferral delivery feature. Read SEC document |
| March 25, 2019 Filed Apr 21, 2023 22:20 UTC Amendment | LEVI STRAUSS & CO LEVI · Entity 3651 | OtherCommon Stock | 77,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025241 · doc4a.xml · nonDerivative · entry 1 Beraud Jill · CIK 0001520061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,330 F1 · security: Immediately prior to the closing of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.